Form 4: Zymeworks Inc. Executive Stock Option and RSU Grant

Kristin Stafford, EVP and CFO of Zymeworks Inc., was granted stock options and restricted stock units on April 6, 2026.

Summary

• Kristin Stafford, Executive Vice President and Chief Financial Officer of Zymeworks Inc., received a grant of stock options and restricted stock units (RSUs) on April 6, 2026.
• The stock options have an exercise price of $25.84 and represent the right to buy 178,000 shares of common stock, with an expiration date of April 5, 2036.
• The RSUs represent the contingent right to receive one share of Zymeworks' common stock upon vesting.
• A portion of the RSUs, totaling 119,000 shares, will vest in four equal annual installments starting on the first anniversary of the grant date.
• Another portion of RSUs, totaling 50,000 shares, will vest in three equal annual installments starting on the first anniversary of the grant date.
• The stock options vest with 25% on the first anniversary of the grant date, and the remaining shares vest in 36 equal monthly installments thereafter.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine grant of equity compensation to an executive officer, typical for companies in this sector, rather than a significant event impacting financial performance or strategic direction.

Positives

• Grant of stock options and RSUs to a key executive (EVP, CFO) indicates continued investment in and retention of leadership.
• The stock options and RSUs provide a long-term incentive for the executive to drive company performance and shareholder value.
• Vesting schedules for both options and RSUs are structured over multiple years, aligning executive interests with long-term company growth.

Risks

• The value of the stock options and RSUs is directly tied to the future performance of Zymeworks Inc.'s stock price, which is subject to market volatility and company-specific risks.
• If the company's stock price does not perform well, the granted equity awards may not provide significant financial benefit to the executive.

Future Outlook

The future outlook for the value of these equity awards depends on the company's stock performance and the executive's continued service through the vesting periods.

Industry Context

StockSavvy.ai notes that the granting of stock options and RSUs to executive officers is a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key talent, aligning their financial interests with long-term shareholder value creation.

Stakeholder Impact

• Shareholders: The grants are a form of compensation and do not directly impact current share count, but their future value is tied to stock performance. Long-term vesting aligns executive interests with shareholder value.
• Employees: This filing is specific to an executive and does not directly impact other employees, though it reflects the company's compensation strategy.
• Management: The executive is incentivized to perform well to realize the value of their equity awards.

Next Steps

• Kristin Stafford will work towards meeting the vesting requirements for the granted stock options and RSUs.
• The company will continue to operate and potentially achieve milestones that could increase the value of the granted equity.

Key Dates

Keywords

Zymeworks Inc., Kristin Stafford, Stock Options, Restricted Stock Units, RSU, Executive Compensation, Form 4, SEC Filing, Equity Awards, Vesting Schedule, CFO